Biopharmaceutical Third-Party Logistics Market Summary
The global biopharmaceutical third-party logistics market size was valued at USD 152.0 billion in 2025 and is projected to grow from USD 161.4 billion in 2026 to USD 258.4 billion by 2033, at a CAGR of 6.9% from 2026 to 2033. North America dominated the market, accounting for the largest share of 41.7% in 2025. The biopharmaceutical third-party logistics (3PL) industry is experiencing robust growth, driven by the expanding commercialization of biologics and biosimilars, increasing demand for temperature-controlled and GDP-compliant logistics infrastructure, rising outsourcing of supply chain operations by pharmaceutical and biotechnology companies, growth in clinical trials and advanced therapies including cell and gene therapies, and continuous investments in digital supply chain technologies for end-to-end product visibility and regulatory compliance.
The increasing complexity of global biopharmaceutical distribution, combined with stringent handling requirements for temperature-sensitive products and growing cross-border pharmaceutical trade, is encouraging manufacturers to partner with specialized third-party logistics providers offering integrated transportation, warehousing, packaging, inventory management, and cold chain capabilities.
The rapid expansion of biologics, biosimilars, and advanced therapies remains one of the primary factors driving market growth. Unlike conventional pharmaceuticals, biologics require specialized transportation, temperature-controlled storage, validated packaging, and continuous monitoring throughout the supply chain to preserve product efficacy and regulatory compliance. The growing commercialization of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies has significantly increased the demand for specialized logistics providers with GDP-certified infrastructure and global distribution networks.
Furthermore, increasing outsourcing of pharmaceutical supply chain operations is another major driver supporting market expansion. Pharmaceutical and biotechnology companies are increasingly relying on specialized third-party logistics providers to optimize distribution efficiency, improve regulatory compliance, reduce operational costs, and enhance supply chain resilience across global markets. Managing highly regulated biopharmaceutical supply chains requires specialized expertise in cold chain management, customs clearance, serialization, inventory control, and last-mile delivery, making outsourcing a cost-effective and scalable solution. Strategic investments and acquisitions across the logistics industry further demonstrate this trend. For instance, in March 2025, DHL announced the acquisition of specialty pharmaceutical logistics provider CryoPDP to strengthen its capabilities in clinical trial logistics, biopharma distribution, and cell and gene therapy transportation, further expanding its integrated healthcare logistics portfolio and specialized cold chain network.
However, the market growth is constrained by the high capital investment required for temperature-controlled infrastructure, stringent global regulatory compliance requirements, and the operational complexity associated with transporting highly sensitive biopharmaceutical products across international markets. Nevertheless, increasing commercialization of advanced therapies, expanding biologics pipelines, growing adoption of digital supply chain technologies, and continued investments in GDP-compliant cold chain infrastructure are expected to create substantial long-term opportunities for biopharmaceutical third-party logistics providers. The market is expected to maintain steady growth as pharmaceutical manufacturers increasingly outsource complex logistics operations to specialized partners capable of delivering secure, compliant, and globally integrated supply chain solutions.
Global Biopharmaceutical Third-party Logistics Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical third-party logistics market report based on supply chain, service type, and region:
- Supply Chain Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Cold Chain Logistics
- Non-cold Chain Logistics
- Service Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Transportation
- Air Freight
- Sea Freight
- Overland
- Warehousing and Storage
- Other Services
- Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Australia
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Supply Chain
- 1.2.2. Service Type
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Top-Down Analysis
- 1.7.3. Bottom-Up Approach
- 1.7.4. Multivariate Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Technological Advancements in Logistics
- 3.2.1.2. Growing Applications of Reverse Logistics in the Biopharmaceutical Industry
- 3.2.1.3. Rising Demand for Cold Chain Logistics
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Compliance Issues While Outsourcing
- 3.2.2.2. Stringent Regulatory Framework
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. Tariff Impact Analysis
- 3.6. Market Analysis Tools
- 3.6.1. Porter's Five Force Analysis
- 3.6.2. PESTEL by SWOT Analysis
Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis
- 4.1. Biopharmaceutical Third-Party Logistics Market, By Supply Chain: Segment Dashboard
- 4.2. Biopharmaceutical Third-Party Logistics Market, By Supply Chain: Movement Analysis
- 4.3. Biopharmaceutical Third-Party Logistics Market Estimates & Forecasts, By Supply Chain, 2021 - 2033 (USD Million/Billion)
- 4.4. Cold Chain Logistics
- 4.4.1. Cold Chain Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 4.5. Non-cold Chain Logistics
- 4.5.1. Non-cold Chain Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis
- 5.1. Biopharmaceutical Third-Party Logistics Market, By Service Type: Segment Dashboard
- 5.2. Biopharmaceutical Third-Party Logistics Market, By Service Type: Movement Analysis
- 5.3. Biopharmaceutical Third-Party Logistics Market Estimates & Forecasts, By Service Type, 2021 - 2033 (USD Million/Billion)
- 5.4. Transportation
- 5.4.1. Transportation Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 5.4.2. Air Freight
- 5.4.2.1. Air Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 5.4.3. Sea Freight
- 5.4.3.1. Sea Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 5.4.4. Overland
- 5.4.4.1. Overland Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 5.5. Warehousing and Storage
- 5.5.1. Warehousing and Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 5.6. Other Services
- 5.6.1. Other Services Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Dashboard
- 6.2. Regional Market Share Analysis, 2025 & 2033
- 6.3. North America
- 6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.3.2. U.S.
- 6.3.2.1. Key Country Dynamics
- 6.3.2.2. Competitive Scenario
- 6.3.2.3. Regulatory Framework
- 6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.3.3. Canada
- 6.3.3.1. Key Country Dynamics
- 6.3.3.2. Competitive Scenario
- 6.3.3.3. Regulatory Framework
- 6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.3.4. Mexico
- 6.3.4.1. Key Country Dynamics
- 6.3.4.2. Competitive Scenario
- 6.3.4.3. Regulatory Framework
- 6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4. Europe
- 6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.2. UK
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Competitive Scenario
- 6.4.2.3. Regulatory Framework
- 6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.3. Germany
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Competitive Scenario
- 6.4.3.3. Regulatory Framework
- 6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.4. France
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Competitive Scenario
- 6.4.4.3. Regulatory Framework
- 6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.5. Italy
- 6.4.5.1. Key Country Dynamics
- 6.4.5.2. Competitive Scenario
- 6.4.5.3. Regulatory Framework
- 6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.6. Spain
- 6.4.6.1. Key Country Dynamics
- 6.4.6.2. Competitive Scenario
- 6.4.6.3. Regulatory Framework
- 6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.7. Denmark
- 6.4.7.1. Key Country Dynamics
- 6.4.7.2. Competitive Scenario
- 6.4.7.3. Regulatory Framework
- 6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.8. Sweden
- 6.4.8.1. Key Country Dynamics
- 6.4.8.2. Competitive Scenario
- 6.4.8.3. Regulatory Framework
- 6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.4.9. Norway
- 6.4.9.1. Key Country Dynamics
- 6.4.9.2. Competitive Scenario
- 6.4.9.3. Regulatory Framework
- 6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.2. Japan
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Competitive Scenario
- 6.5.2.3. Regulatory Framework
- 6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.3. China
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Competitive Scenario
- 6.5.3.3. Regulatory Framework
- 6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.4. India
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Competitive Scenario
- 6.5.4.3. Regulatory Framework
- 6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.5. Australia
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Competitive Scenario
- 6.5.5.3. Regulatory Framework
- 6.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.6. Thailand
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Competitive Scenario
- 6.5.6.3. Regulatory Framework
- 6.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.5.7. South Korea
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Competitive Scenario
- 6.5.7.3. Regulatory Framework
- 6.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.6. Latin America
- 6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.6.2. Brazil
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Competitive Scenario
- 6.6.2.3. Regulatory Framework
- 6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.6.3. Argentina
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Competitive Scenario
- 6.6.3.3. Regulatory Framework
- 6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7. MEA
- 6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.2. South Africa
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Competitive Scenario
- 6.7.2.3. Regulatory Framework
- 6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.3. UAE
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Competitive Scenario
- 6.7.3.3. Regulatory Framework
- 6.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.4. Saudi Arabia
- 6.7.4.1. Key Country Dynamics
- 6.7.4.2. Competitive Scenario
- 6.7.4.3. Regulatory Framework
- 6.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.5. Kuwait
- 6.7.5.1. Key Country Dynamics
- 6.7.5.2. Competitive Scenario
- 6.7.5.3. Regulatory Framework
- 6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.6. Qatar
- 6.7.6.1. Key Country Dynamics
- 6.7.6.2. Competitive Scenario
- 6.7.6.3. Regulatory Framework
- 6.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
- 6.7.7. Oman
- 6.7.7.1. Key Country Dynamics
- 6.7.7.2. Competitive Scenario
- 6.7.7.3. Regulatory Framework
- 6.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
Chapter 7. Competitive Landscape
- 7.1. Key Participant Categorization
- 7.1.1. Market Leaders
- 7.1.2. Emerging Players
- 7.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
- 7.3. Company Profiles
- 7.3.1. DHL International GmbH
- 7.3.1.1. Company Overview
- 7.3.1.2. Financial Performance
- 7.3.1.3. Service Benchmarking
- 7.3.1.4. Strategic Initiatives
- 7.3.2. SF Express
- 7.3.2.1. Company Overview
- 7.3.2.2. Financial Performance
- 7.3.2.3. Service Benchmarking
- 7.3.2.4. Strategic Initiatives
- 7.3.3. FedEx
- 7.3.3.1. Company Overview
- 7.3.3.2. Financial Performance
- 7.3.3.3. Service Benchmarking
- 7.3.3.4. Strategic Initiatives
- 7.3.4. United Parcel Service of America, Inc.
- 7.3.4.1. Company Overview
- 7.3.4.2. Financial Performance
- 7.3.4.3. Service Benchmarking
- 7.3.4.4. Strategic Initiatives
- 7.3.5. Cencora, Inc.
- 7.3.5.1. Company Overview
- 7.3.5.2. Financial Performance
- 7.3.5.3. Service Benchmarking
- 7.3.5.4. Strategic Initiatives
- 7.3.6. DB Schenker
- 7.3.6.1. Company Overview
- 7.3.6.2. Financial Performance
- 7.3.6.3. Service Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. Kuehne and Nagel
- 7.3.7.1. Company Overview
- 7.3.7.2. Financial Performance
- 7.3.7.3. Service Benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. Kerry Logistics Network Limited
- 7.3.8.1. Company Overview
- 7.3.8.2. Financial Performance
- 7.3.8.3. Service Benchmarking
- 7.3.8.4. Strategic Initiatives
- 7.3.9. Agility Public Warehousing Company K.S.C.P.
- 7.3.9.1. Company Overview
- 7.3.9.2. Financial Performance
- 7.3.9.3. Service Benchmarking
- 7.3.9.4. Strategic Initiatives